Ion Channel Drug Developer Maxion Therapeutics Appoints Eva-Lotta Allan as Chair of its Board of Directors
Eva-Lotta Allan, Chair, Board of Directors, Maxion Therapeutics, commented: "I'm delighted to be appointed to Maxion at such an exciting time in its development.
- Eva-Lotta Allan, Chair, Board of Directors, Maxion Therapeutics, commented: "I'm delighted to be appointed to Maxion at such an exciting time in its development.
- I look forward to working with the Board of Directors and the rest of the Maxion team to help improve patients' lives while creating value for our shareholders."
- KnotBody technology combines the benefits of naturally occurring mini-proteins, which have ion channel modulating activity, with antibodies, using state-of-the-art phage and mammalian display technologies.
- The resulting fusion protein, which combines the drug-like benefits of both molecules, helps address key challenges in ion channel and GPCR drug discovery.